On April 4, 2020, Phoenix TV broadcast a report on Yiling Pharmaceutical. It was reported that the global epidemic continued to worsen. At the China-Europe anti-epidemic exchange meeting, the recovery rate of patients treated with Lianhua Qingwen Capsule of Yiling Pharmaceutical co., LTD was as high as 91.5 percent, which has become a hot spot. Since 2004, Lianhua Qingwen Capsule has been listed by the national health commission of China, the state administration of traditional Chinese medicine and other departments in the treatment of influenza and other respiratory diseases for more than 20 times. It has played an important role in the prevention and control of major epidemics. On March 30, Lianhua Qingwen Capsule was approved by the ministry of health of Thailand for the registration of modern herbal medicine, which indicated that Yiling pharmaceutical co., a representative of modern Chinese medicine enterprises in China, had the qualification to sell Lianhua Qingwen Capsule as a drug in the Thai market.
Recently, Shijiazhuang Yiling Pharmaceutical Co, Ltd. announced that the ministry of foreign affairs of the People's Republic of China has purchased 700,000 boxes of Lianhua Qingwen and distribute them to each Chinese embassy. The health packages for Chinese students studying overseas are also equipped with Lianhua Qingwen.
The outbreak of the global coronavirus epidemic has shown the important role that can be played by traditional Chinese medicine (TCM). The vaccine will not be available in a short time, and demand for TCM has been rising in overseas markets, as it provides a valuable alternative.
A source close to Yiling Pharmaceutical (Yiling) told the Global Times on Monday that at present, there is a significant increase in demand for the company's Lianhuaqingwen capsules in six countries.
SHIJIAZHUANG, CHINA / ACCESSWIRE / March 20, 2020 / COVID-19 epidemic continues worldwide. Real-time statistics from the World Health Organization show that there are more than 180,000 confirmed cases worldwide, including more than 100,000 confirmed cases outside China. At a press conference held on March 17 by the joint defense and control mechanism of the State Council of China, the reporter asked: “It is reported that the Chinese expert team carried Chinese traditional medicine such as Lianhua Qingwen when assisting Italy and other countries. What is the current treatment situation of Chinese medicine for patients with COVID-19 abroad? ”
When the Academician of Chinese Academy of Engineering and the President of Tianjin University of Traditional Chinese Medicine Zhang Boli was interviewed by the media in Wuhan on April 15, he mentioned that the National Medical Products Administration had approved the treatment of COVID-2019 as the new indication of "three kinds of drugs", which are Jinhua Qinggan Granules, Lianhua Qingwen Granules and Capsules, and Xuebijing Injections.